Until recently, the concept that the genetic status of an individual was fixed and unalterable was widely accepted. However, in the last several years, advances in human genetics, cell biology, and gene therapy have resulted in a fundamental change in this therapeutic paradigm. Today’s physicians are not only using gene and cell therapies to help patients live better with their genetic constitutions, but are also using novel therapies to alter the genetic makeup of the patient.
In ShareVault‘s upcoming webinar, Mike Rice of Defined Health will discuss recent advances in gene and stem cell therapies with particular emphasis on the therapeutic potentials and the significant hurdles that must be overcome for effective treatment of diseases.
Breakthrough gene and cell therapies for ultra-rare disorders are expected to gain FDA approval in the next couple of years including:
Join Sharevault from the comfort of your desk on Tuesday, January 16th, 2018 as they explore the potential, advances and availability of these therapies and the implications that “one-time treatments” will have on pricing, risk-sharing schemes, and ultimately, market valuations and deal making.